Related Experiment Videos
[Drug therapy of erectile dysfunction--the current status]
1Klinik für Urologie und Kinderurologie, Medizinische Hochschule, Hannover. schultheiss.dirk@mh-hannover.de
Der Urologe. Ausg. A
|October 22, 2003
Summary
Oral phosphodiesterase type 5 (PDE-5) inhibitors like Sildenafil have revolutionized erectile dysfunction (ED) treatment. Intra-cavernosal prostaglandin E1 (PGE(1)) remains the gold standard for cases unresponsive to oral ED medications.
Area of Science:
- Pharmacology
- Urology
- Andrology
Background:
- Erectile dysfunction (ED) treatment has evolved significantly with the advent of oral therapies.
- Historically, oral and local applications were considered for ED management.
Purpose of the Study:
- To review the current landscape of ED pharmacotherapy.
- To compare the efficacy and role of different oral and local ED treatments.
Main Methods:
- Review of existing literature on ED pharmacotherapies.
- Analysis of the impact of PDE-5 inhibitors on ED treatment strategies.
Main Results:
- Sildenafil, Tadalafil, and Vardenafil (PDE-5 inhibitors) are highly potent oral ED therapies.
- Older oral agents like Yohimbine have limited efficacy.
- Intra-urethral prostaglandin E1 (PGE(1)) is reserved for specific cases.
- Intra-cavernosal PGE(1) is the gold standard for refractory ED.
Conclusions:
- Oral PDE-5 inhibitors represent the primary pharmacotherapy for ED.
- Intra-cavernosal PGE(1) remains crucial for patients who cannot use or do not respond to oral ED treatments.